Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Death of a unicorn
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Upcoming events – Crucial data for Neurocrine and Redhill
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Arbutus’s hep B handicap grows
Arbutus Biopharma already looked second best to Arrowhead Pharmaceuticals in the race to develop a functional cure for hepatitis B. New data have made the former’s task…
Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
Looking for new mechanisms to cure hepatitis B
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Abivax seeks funds to follow another fork
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
Go or no go? Roche, Lilly and Teva await big regulatory readouts
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Biontech gets big pharma to take on Moderna
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.